BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 35121646)

  • 21. Importance of Multiparametric Evaluation of Immune-Related T-Cell Markers in Renal-Cell Carcinoma.
    Kawashima A; Uemura M; Nonomura N
    Clin Genitourin Cancer; 2019 Dec; 17(6):e1147-e1152. PubMed ID: 31473121
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cancer-Associated Fibroblasts Affect Intratumoral CD8
    Kato T; Noma K; Ohara T; Kashima H; Katsura Y; Sato H; Komoto S; Katsube R; Ninomiya T; Tazawa H; Shirakawa Y; Fujiwara T
    Clin Cancer Res; 2018 Oct; 24(19):4820-4833. PubMed ID: 29921731
    [No Abstract]   [Full Text] [Related]  

  • 23. Progressive immune dysfunction with advancing disease stage in renal cell carcinoma.
    Braun DA; Street K; Burke KP; Cookmeyer DL; Denize T; Pedersen CB; Gohil SH; Schindler N; Pomerance L; Hirsch L; Bakouny Z; Hou Y; Forman J; Huang T; Li S; Cui A; Keskin DB; Steinharter J; Bouchard G; Sun M; Pimenta EM; Xu W; Mahoney KM; McGregor BA; Hirsch MS; Chang SL; Livak KJ; McDermott DF; Shukla SA; Olsen LR; Signoretti S; Sharpe AH; Irizarry RA; Choueiri TK; Wu CJ
    Cancer Cell; 2021 May; 39(5):632-648.e8. PubMed ID: 33711273
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Integrated single-cell and bulk sequencing analyses with experimental validation identify the prognostic and immunological implications of CD226 in pan-cancer.
    Ma P; Sun W
    J Cancer Res Clin Oncol; 2023 Nov; 149(16):14597-14617. PubMed ID: 37580402
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tim-3 expression represents dysfunctional tumor infiltrating T cells in renal cell carcinoma.
    Cai C; Xu YF; Wu ZJ; Dong Q; Li MY; Olson JC; Rabinowitz YM; Wang LH; Sun Y
    World J Urol; 2016 Apr; 34(4):561-7. PubMed ID: 26253654
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune infiltration in renal cell carcinoma.
    Zhang S; Zhang E; Long J; Hu Z; Peng J; Liu L; Tang F; Li L; Ouyang Y; Zeng Z
    Cancer Sci; 2019 May; 110(5):1564-1572. PubMed ID: 30861269
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multidimensional Analyses of Tumor Immune Microenvironment Reveal the Possible Rationality of Immunotherapy and Identify High Immunotherapy Response Subtypes for Renal Papillary Cell Carcinoma.
    Wei B; Yu M; Yao J; Jiang M; An J; Yang J; Lin J; Zhao Y; Zhu Y
    Front Immunol; 2021; 12():657951. PubMed ID: 34531849
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune Cell Infiltration and Identifying Genes of Prognostic Value in the Papillary Renal Cell Carcinoma Microenvironment by Bioinformatics Analysis.
    Liu T; Zhang M; Sun D
    Biomed Res Int; 2020; 2020():5019746. PubMed ID: 32775427
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PD-L1 expression and infiltration by CD4
    Lee HJ; Shin DH; Lee YJ; Lee SJ; Hwang CS; Kim A; Park WY; Lee JH; Choi KU; Kim JY; Lee CH; Sol MY; Park SW
    Histopathology; 2020 Apr; 76(5):714-721. PubMed ID: 31841221
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Downregulation of S100A11 promotes T cell infiltration by regulating cancer-associated fibroblasts in prostate cancer.
    Han D; Guo C; Cheng H; Lu J; Hou Z; Zhang X; Luo Y; Zhang B; Zhao W; Shang P
    Int Immunopharmacol; 2024 Feb; 128():111323. PubMed ID: 38286714
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD40 expression in renal cell carcinoma is associated with tumor apoptosis, CD8(+) T cell frequency and patient survival.
    Weiss JM; Gregory Alvord W; QuiƱones OA; Stauffer JK; Wiltrout RH
    Hum Immunol; 2014 Jul; 75(7):614-20. PubMed ID: 24801648
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Integrated analysis of immune-related gene subtype and immune index for immunotherapy in clear cell renal cell carcinoma.
    Bai D; Chen S; Feng H; Yin A; Lu J; Ma Y; Sugiyama H
    Pathol Res Pract; 2021 Sep; 225():153557. PubMed ID: 34329838
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor-agnostic transcriptome-based classifier identifies spatial infiltration patterns of CD8+T cells in the tumor microenvironment and predicts clinical outcome in early-phase and late-phase clinical trials.
    Roller A; Davydov II; Schwalie PC; Serrano-Serrano ML; Heller A; Staedler N; Ferreira CS; Dietmann G; Klaman I; Valdeolivas A; Korski K; Cannarile MA
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38649280
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Listeria-based immunotherapy directed against CD105 exerts anti-angiogenic and anti-tumor efficacy in renal cell carcinoma.
    Oladejo M; Nguyen HM; Silwal A; Reese B; Paulishak W; Markiewski MM; Wood LM
    Front Immunol; 2022; 13():1038807. PubMed ID: 36439126
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of biomarkers related to CD8
    Lin J; Yu M; Xu X; Wang Y; Xing H; An J; Yang J; Tang C; Sun D; Zhu Y
    Aging (Albany NY); 2020 Feb; 12(4):3694-3712. PubMed ID: 32081834
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DAB2IP Plays Important Clinical Significance and Correlates With Immune Infiltration in Renal Cell Carcinoma.
    Cao H; Zhang J; Wang W
    Technol Cancer Res Treat; 2020; 19():1533033820936682. PubMed ID: 32583730
    [TBL] [Abstract][Full Text] [Related]  

  • 37. GGT5: a potential immunotherapy response inhibitor in gastric cancer by modulating GSH metabolism and sustaining memory CD8+ T cell infiltration.
    Zhao W; Liang Z; Yao Y; Ge Y; An G; Duan L; Yao J
    Cancer Immunol Immunother; 2024 May; 73(7):131. PubMed ID: 38748299
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Abundant CD8+ tumor infiltrating lymphocytes and beta-2-microglobulin are associated with better outcome and response to interleukin-2 therapy in advanced stage clear cell renal cell carcinoma.
    Davis D; Tretiakova MS; Kizzar C; Woltjer R; Krajbich V; Tykodi SS; Lanciault C; Andeen NK
    Ann Diagn Pathol; 2020 Aug; 47():151537. PubMed ID: 32454441
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Single-Cell Transcriptomic Analysis Reveals a Tumor-Reactive T Cell Signature Associated With Clinical Outcome and Immunotherapy Response In Melanoma.
    Yan M; Hu J; Ping Y; Xu L; Liao G; Jiang Z; Pang B; Sun S; Zhang Y; Xiao Y; Li X
    Front Immunol; 2021; 12():758288. PubMed ID: 34804045
    [TBL] [Abstract][Full Text] [Related]  

  • 40. miR-29b and miR-198 overexpression in CD8+ T cells of renal cell carcinoma patients down-modulates JAK3 and MCL-1 leading to immune dysfunction.
    Gigante M; Pontrelli P; Herr W; Gigante M; D'Avenia M; Zaza G; Cavalcanti E; Accetturo M; Lucarelli G; Carrieri G; Battaglia M; Storkus WJ; Gesualdo L; Ranieri E
    J Transl Med; 2016 Apr; 14():84. PubMed ID: 27063186
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.